Physician profile
Deepa Chintala
NPI 1659582575
$3,435.75
in general payments reported to CMS, 2019-2025
36 companies · $351 in 2025
The $351 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $519 · 2021: $599 · 2022: $441 · 2023: $563 · 2024: $461 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,375.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $864.30 | 2019-2024 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $285.20 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $254.74 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.81 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $173.59 | 2024-2025 | |
| Lilly USA, LLC | $160.68 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $148.00 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Itamar Medical INC | $144.36 | 2021-2023 | Watchpatone |
| Esperion Therapeutics, INC. | $121.51 | 2020-2024 | Nexletol |
| Bausch Health US, LLC | $105.67 | 2020-2022 | |
| Pfizer INC. | $87.49 | 2023-2024 | |
| Abbott Laboratories | $77.93 | 2019-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $66.68 | 2020-2024 | Ozempic, Rybelsus |
| Cleerly, INC. | $63.23 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Novartis Pharmaceuticals Corporation | $60.48 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $55.81 | 2024-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $49.12 | 2021-2023 | Ubrelvy |
| Glaxosmithkline, LLC. | $47.00 | 2021-2023 | Shingrix, Bexsero |
| Ibsa Pharma INC. | $43.36 | 2021-2024 | Tirosint, Licart, Licart |
| Amgen INC. | $39.96 | 2023 | Repatha, Otezla |
| Eisai INC. | $39.57 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $37.98 | 2022-2023 | Rexulti |
| Genentech USA, INC. | $37.74 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.31 | 2021-2024 | Trintellix |
| Braintree Laboratories, INC. | $24.84 | 2023 | Suflave |
| Shire North American Group INC | $22.94 | 2019 | |
| Misonix INC | $18.55 | 2019 | |
| Althera Pharmaceuticals LLC | $17.40 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.40 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.08 | 2025 | Zoryve |
| Daiichi Sankyo INC. | $15.96 | 2021 | |
| Medtronic Vascular, INC. | $15.65 | 2020 | |
| Horizon Therapeutics Plc | $15.59 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.13 | 2022 | |
| Hologic Sales and Service, LLC | $13.75 | 2022 | |
| Allergan, INC. | $12.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepa Chintala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.